KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Common Equity (2016 - 2026)

Supernus Pharmaceuticals has reported Common Equity over the past 15 years, most recently at $1.1 billion for Q4 2025.

  • Quarterly Common Equity rose 2.51% to $1.1 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.1 billion through Dec 2025, up 2.51% year-over-year, with the annual reading at $1.1 billion for FY2025, 2.51% up from the prior year.
  • Common Equity was $1.1 billion for Q4 2025 at Supernus Pharmaceuticals, up from $1.0 billion in the prior quarter.
  • Over five years, Common Equity peaked at $1.1 billion in Q2 2025 and troughed at $754.4 million in Q1 2021.
  • The 5-year median for Common Equity is $916.0 million (2023), against an average of $918.8 million.
  • Year-over-year, Common Equity grew 23.0% in 2021 and then rose 1.87% in 2024.
  • A 5-year view of Common Equity shows it stood at $815.9 million in 2021, then rose by 8.62% to $886.2 million in 2022, then rose by 3.98% to $921.5 million in 2023, then increased by 12.39% to $1.0 billion in 2024, then rose by 2.51% to $1.1 billion in 2025.
  • Per Business Quant, the three most recent readings for SUPN's Common Equity are $1.1 billion (Q4 2025), $1.0 billion (Q3 2025), and $1.1 billion (Q2 2025).